Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic …
JM Hare, JE Fishman, G Gerstenblith, DLDF Velazquez… - Jama, 2012 - jamanetwork.com
Context Mesenchymal stem cells (MSCs) are under evaluation as a therapy for ischemic
cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible;
however, their safety and efficacy have not been compared. Objective To test whether
allogeneic MSCs are as safe and effective as autologous MSCs in patients with left
ventricular (LV) dysfunction due to ICM. Design, Setting, and Patients A phase 1/2
randomized comparison (POSEIDON study) in a US tertiary-care referral hospital of …
cardiomyopathy (ICM). Both autologous and allogeneic MSC therapies are possible;
however, their safety and efficacy have not been compared. Objective To test whether
allogeneic MSCs are as safe and effective as autologous MSCs in patients with left
ventricular (LV) dysfunction due to ICM. Design, Setting, and Patients A phase 1/2
randomized comparison (POSEIDON study) in a US tertiary-care referral hospital of …
